Skip to main content

Dr. Micheal Hebert counsels clients on strategies for maximizing intellectual property protection and leveraging that protection in several areas of life sciences. His practice includes drafting and prosecuting patent applications in genetics, gene therapy, personalized medicine, pharmaceuticals, virology, antibodies, stem cells, and microbiology. Micheal also has experience conducting due diligence research and analysis for freedom-to-operate investigations, patent validity opinions, patentability opinions, and technology licensing.

Micheal's practice also includes an emphasis on licensing and other commercial transactions in the life sciences. He assists clients in matters related to transfer of intellectual property rights and collaborations between parties, including drafting and negotiating license agreements and joint development agreements. He also performs due diligence assessments of transactions involving the acquisition and transfer of intellectual property rights.


  • Life sciences and health care
  • Patent portfolio management and strategic counseling
  • IP due diligence
  • Biotechnology



  • Served as IP counsel in connection with the $84 million initial public offering of Hookipa Pharma Inc. (NASDAQ: HOOK).°
  • Represented Bellicum Pharmaceuticals, Inc. in the development and prosecution of global patent portfolios related to cellular immuno-oncology (IO) and immunotherapies, including BPX-601 (PSCA CAR-T) and BPX-603 (Her2 CAR-T) clinical candidates utilizing the Bellicum’s proprietary GoCAR™ technology.°
  • Represented NGM Biopharmaceuticals, Inc. in the development of a global patent portfolio for antibodies to beta-klotho for the treatment of diabetes and other metabolic disorders.°
  • Represented Genomatica on a range of licensing and joint development agreements with multiple partners worldwide.°
  • Assisted Hookipa Biotech AG in the development of a worldwide patent portfolio.°
  • Represents Genomatica in the development of a worldwide patent portfolio related to methods of producing high-volume basic and intermediate chemicals from alternative feedstocks, such as sugars and cellulosic biomass, using engineered microorganisms.
  • Managed Genentech Inc.'s global patent portfolio and prosecuted patent applications related to therapeutic antibodies.°

°The above representations were handled by Mr. Hebert prior to his joining Greenberg Traurig, LLP.

  • Postdoctoral Fellow, Stanford University School of Medicine, 2005-2007

Recognition & Leadership

  • Listed, The Best Lawyers in America, "Ones to Watch," Health Care Law, 2021-2024
  • Recipient, NIH, National Service Award, 2005
  • Recipient, National Hemophilia Foundation Fellowship, 2006


  • J.D., University of San Diego School of Law, 2015
  • Ph.D., Human and Molecular Genetics, 2005
  • B.S., Cellular Biochemistry, 1998
  • California
  • U.S. Patent and Trademark Office